Plasma Supply Falling Behind Demand: Kristopher Jonas Sounds the Alarm
Kristopher Jonas, CEO/President of Proesis Biologics, posted on LinkedIn:
”You know what’s scary?
The growing gap between how much plasma-derived medicine the world needs and how much plasma we’re actually collecting.
Global demand for immunoglobulins (IG) continues to climb 6–8% each year. And that’s not even factoring in underutilization in low to middle-income countries.
Fractionators are bringing new manufacturing capacity online across the U.S. and Europe.
But all that capacity still depends on one thing – human plasma – and the supply side isn’t keeping pace.
That’s where independent collectors come in.
We’re the flexible link in the chain, able to expand quickly, reach new donor communities, and help ensure the growing global infrastructure doesn’t sit idle waiting for plasma.
Not spooky. Just real.
And it’s why what we’re building at Proesis Bio matters.”
Keep up with Hemostasis Today.
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC
-
Apr 9, 2026, 18:21New Clinical Practice Guideline on Anticoagulant Prophylaxis in Pediatric Patients at Risk of VTE – ISTH